Formulation solubilizing water-insoluble agents and preparation method thereof
514/559 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
Chalcogen attached indirectly to the 9- position of the purine ring system by acyclic nonionic bonding
Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI
Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)
Higher fatty acid or salt thereof
Ring containing

514/54 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)
Carbohydrate (i.e., saccharide radical containing) DOAI
Polysaccharide

514/449 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
Chalcogen bonded directly to carbon of the hetero ring of the quinoline ring system
Having -C(=X)-, wherein X is chalcogen, bonded directly to carbon of the hetero ring of the quinoline ring system
Oxygen containing hetero ring

514/182 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)
Cyclopentanohydrophenanthrene ring system DOAI
Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system

514/44 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)
Carbohydrate (i.e., saccharide radical containing) DOAI
N-glycoside
Nitrogen containing hetero ring
Polynucleotide (e.g., RNA, DNA, etc.)

514/178 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)
Cyclopentanohydrophenanthrene ring system DOAI
Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system
Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system

Database: US Patents
Comments: 0
Votes:32